William Arsani
Known title: DirectorCIK: 0001848372
William Arsani's purchase track record
How the stock did after each of William Arsani's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since August 31, 2021
Stock higher 6 months later
67%
3 months: 33%
Median 6-month return
+4.5%
3 months: -0.4%
Beat the S&P 500
67%
median +16.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/28/2023 | DSGN | $5.37M | -0.4% | +30.9% | +14.3% |
| 3/21/2022 | DSGN | $475K | -19.2% | +4.5% | -12.6% |
| 8/31/2021 | DSGN | $618K | +6.5% | -10.9% | -4.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DSGN | ▼ Sell | Open Market | 345,000 | $1.8M | 8/13/2025 | View on chart |
| DSGN | ▼ Sell | Open Market | 217,627 | $1.1M | 8/13/2025 | View on chart |
| DSGN | ▼ Sell | Open Market | 814,874 | $3.5M | 8/9/2024 | View on chart |
| DSGN | ▲ Buy | Open Market | 1,960,000 | $4.8M | 8/29/2023 | View on chart |
| DSGN | ▲ Buy | Open Market | 275,000 | $591K | 8/28/2023 | View on chart |
| DSGN | ▲ Buy | Open Market | 25,000 | $475K | 3/21/2022 | View on chart |
| DSGN | ▲ Buy | Open Market | 40,000 | $618K | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Design Therapeutics to Present at Cantor Fitzgerald Healthcare Conference
Design Therapeutics will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference. These events give companies a platform to engage with institutional investors and present their programs. The stock has traded within a 52-week range of $5.28 to $17.25, with analysts maintaining an average price target of $21.00.
Design Therapeutics to Present at Cantor Fitzgerald Healthcare Conference. Design Therapeutics will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference. These events give companies a platform to engage with institutional investors and present their programs. The stock has traded within a 52-week range of $5.28 to $17.25, with analysts maintaining an average price target of $21.00.